These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 6383687)
41. Treatment of type IIa and type V hyperlipoproteinemia and of a normal volunteer by continuous LDL-apheresis. Riesen WF; Sturzenegger E; Imhof C; Descoeudres C; Mordasini R; Oetliker OH Prog Clin Biol Res; 1988; 255():337-46. PubMed ID: 3422496 [No Abstract] [Full Text] [Related]
42. [Dietary treatment of patients with familial hyperlipoproteinemias]. Solovév EIu; Rozhkova TA; Koshechkin VA; Pogozhaeva AV Kardiologiia; 1992; 32(11-12):56-8. PubMed ID: 1297883 [No Abstract] [Full Text] [Related]
43. Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study. Castaño G; Mas R; Fernández L; Illnait J; Gámez R; Alvarez E Int J Clin Pharmacol Res; 2001; 21(1):43-57. PubMed ID: 11708574 [TBL] [Abstract][Full Text] [Related]
44. An approach to the management of hyperlipoproteinemia. Hoeg JM; Gregg RE; Brewer HB JAMA; 1986 Jan 24-31; 255(4):512-21. PubMed ID: 3510334 [TBL] [Abstract][Full Text] [Related]
45. Effects of phytosterol ester-enriched vegetable oil on plasma lipoproteins in healthy men. Seki S; Hidaka I; Kojima K; Yoshino H; Aoyama T; Okazaki M; Kondo K Asia Pac J Clin Nutr; 2003; 12(3):282-91. PubMed ID: 14505991 [TBL] [Abstract][Full Text] [Related]
46. Effect of dietary treatment on the plasma levels of lipids, lipoprotein cholesterol and LDL B protein in children with type II hyperlipoproteinemia. Kwiterovich PO; Bachorik PS; Franklin FA; Margolis S; Georgopoulos L; Teng B; Sniderman AD Prog Clin Biol Res; 1985; 188():123-37. PubMed ID: 4059254 [TBL] [Abstract][Full Text] [Related]
47. The hypolipidemic effect of locust bean gum food products in familial hypercholesterolemic adults and children. Zavoral JH; Hannan P; Fields DJ; Hanson MN; Frantz ID; Kuba K; Elmer P; Jacobs DR Am J Clin Nutr; 1983 Aug; 38(2):285-94. PubMed ID: 6308996 [TBL] [Abstract][Full Text] [Related]
48. Application of soluble dietary fibres in treatment of hyperlipoproteinemias. Grudeva-Popova J; Krachanova M; Djurdjev A; Krachanov C Folia Med (Plovdiv); 1997; 39(1):39-43. PubMed ID: 9141790 [TBL] [Abstract][Full Text] [Related]
49. Premature development of iliac artery stenosis in asymptomatic type II hyperlipoproteinemia. Rubba P; Postiglione A; De Simone B; Faccenda F; Riccardi G; Mancini M Arteriosclerosis; 1984; 4(6):625-9. PubMed ID: 6391445 [TBL] [Abstract][Full Text] [Related]
50. Loss of dental enamel in a patient taking cholestyramine. Curtis DM; Driscoll DJ; Goldman DH; Weidman WH Mayo Clin Proc; 1991 Nov; 66(11):1131. PubMed ID: 1943246 [TBL] [Abstract][Full Text] [Related]
51. Effect of oral neomycin treatment of hyperlipoproteinemia on antibiotic susceptibilities of stool enteric flora. Witebsky FG; Wu TC; Hoeg JM Am J Cardiol; 1986 Aug; 58(3):375-6. PubMed ID: 3526858 [No Abstract] [Full Text] [Related]
52. A comparative study of the effects of cholestyramine and neomycin in the treatment of type II hyperlipoproteinaemia. Schade RW; van't Laar A; Majoor CL; Jansen AP Acta Med Scand; 1976; 199(3):175-80. PubMed ID: 176876 [TBL] [Abstract][Full Text] [Related]
53. Pre-entry characteristics of participants in the Lipid Research Clinics' Coronary Primary Prevention Trial. J Chronic Dis; 1983; 36(6):467-79. PubMed ID: 6863470 [TBL] [Abstract][Full Text] [Related]
54. National Heart, Lung, and Blood Institute type II Coronary Intervention Study: design, methods, and baseline characteristics. Brensike JF; Kelsey SF; Passamani ER; Fisher MR; Richardson JM; Loh IK; Stone NJ; Aldrich RF; Battaglini JW; Moriarty DJ; Myrianthopoulos MB; Detre KM; Epstein SE; Levy RI Control Clin Trials; 1982 Jun; 3(2):91-111. PubMed ID: 6749427 [TBL] [Abstract][Full Text] [Related]